Robert W. Baird Forecasts Strong Price Appreciation for LivaNova (NASDAQ:LIVN) Stock

LivaNova (NASDAQ:LIVN) had its price objective lifted by research analysts at Robert W. Baird from $61.00 to $63.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target points to a potential upside of 28.14% from the company’s previous close.

A number of other research analysts also recently commented on the company. The Goldman Sachs Group set a $55.00 price objective on LivaNova and gave the company a “neutral” rating in a report on Wednesday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. Barclays increased their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.00.

LivaNova Stock Down 3.2%

NASDAQ LIVN traded down $1.65 during trading hours on Thursday, hitting $49.17. 178,278 shares of the company were exchanged, compared to its average volume of 665,193. The company has a 50 day moving average of $54.25 and a two-hundred day moving average of $48.13. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. LivaNova has a 52-week low of $32.48 and a 52-week high of $58.91. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -12.64 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.21. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The company had revenue of $352.50 million for the quarter, compared to the consensus estimate of $332.20 million. During the same quarter in the prior year, the business earned $0.93 EPS. LivaNova’s revenue was up 10.6% on a year-over-year basis. Equities research analysts anticipate that LivaNova will post 2.85 earnings per share for the current year.

Institutional Trading of LivaNova

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in LivaNova by 182.5% during the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after acquiring an additional 407 shares during the period. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC lifted its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the period. CWM LLC lifted its position in LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after acquiring an additional 299 shares during the period. Finally, UMB Bank n.a. lifted its position in LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.